https://www.selleckchem.com/products/ml210.html
Evidence links COVID-19 severity to hyper-inflammation. Treatment with tocilizumab, a monoclonal antibody directed against the interleukin-6 (IL-6) receptor, was shown to lead to clinical improvement in patients with severe COVID-19. We, therefore, performed the present systematic review and meta-analysis to investigate whether the circulating levels of IL-6 is a reliable indicator of disease severity among patients affected with COVID-19. A systematic search was conducted in PubMed, Scopus, Web of Science, and Google Scholar on April 19,
Like
Comment
Share
